LiveCareer-Resume

pharmacogenomics lab manager resume example with 20+ years of experience

Jessica Claire
Montgomery Street, San Francisco, CA 94105 609 Johnson Ave., 49204, Tulsa, OK
Home: (555) 432-1000 - Cell: - resumesample@example.com - - -
Professional Summary
I have 15 years of research experience in various fields such as Microbiology, Immunology, Pathology, Infectious Diseases and Cancer Research. My major focus has been on discovering and developing novel prophylactic and therapeutic agents against infectious diseases and evaluating novel non-invasive biomarkers for early cancer detection. In my current role, I am involved in managing pharmacogenomics lab operations including various aspects of technical, QA/QC and management roles.
Skills
  • Analytical thinker
  • Accomplished leader
  • Promotes positive behavior
  • Independent judgment and decision making
  • Strong presentation skills
  • Promotes positive behavior
  •  

  • Excellent Team Player
Work History
03/2016 to Present
Pharmacogenomics Lab Manager Memorial Health Decatur, IL,
  • Working on personalizing pain medications for clinical patients to prevent adverse drug reactions.
  • Isolating the DNA from the buccal swabs of patients undergoing pain therapy in different clinics across USA.
  • Genotyping the isolated DNA using the state of the art open array profiling for 60 Single Nucleotide Polymorphisms (SNPs) that have a significant impact on metabolism of codeine related drugs.
  • Quantifying the CYP2D6 gene levels to arrive at right CYP2D6 star alleles that have a major role in drug dosing.
  • Exploring the role of other drug metabolizing enzymes that play a critical role in the treatment of chronic pain.
  • Performing Quality control/ Quality Assurance, managing everyday laboratory operations, writing the Standard Operating protocols (SOPs), and maintaining the facility in accordance with Commission on Office Laboratory Accreditation (COLA) guidelines.
01/2014 to 02/2016
Instructor University Of Michigan Ann Arbor, MI,
  • Worked on developing non-invasive biomarkers for advanced prostate cancer patients.
  • Standardized protocols for isolating cell free DNA and exosomal RNA from patient plasma and urine samples.
  • Performed next generation sequencing (NGS) on cell-free DNA of prostate cancer patient samples and analyzed using the bioinformatics pipelines.
  • Developed quantitative PCR/droplet digital PCR (ddPCR) techniques for validating selected targets from NGS derived data.
  • Developed a ddPCR to examine androgen receptors and its variants of clinical significance from patient's urine samples.
  • Understanding various pathways involved in prostate cancer progression in order to develop better therapeutic approaches Jessica Claire, DVM, MS, PhD, DACVM, MB (ASCP) CM.
02/2008 to 01/2014
Research Fellow Hospital For Special Surgery Long Island, NY,
  • Identified and characterized envelopes of simian immunodeficiency virus (SIV) from vesicular stomatitis virus (VSV) vaccinated and SIVE660 challenged macaques using single genome amplification (SGA) technique.
  • Analyzed and Interpreted the results using various phylogenetic techniques for characterizing the envelope sequences of founder/transmitted viruses.
  • Performed Fluorescence-activated cell sorting (FACS) for examining the dynamics of CD4 and CD8T cells in peripheral blood and gut -derived lymphocytes of SIV infected macaques.
  • Analyzed antibody responses from SIV infected macaques in the peripheral blood, gut and lymphnode biopsies.
  • Characterized T cell and B cell responses in Mycobacterium tuberculosis(Mtb) infected macaques using flow cytometry.
  • Standardized techniques for isolating dendritic cells from NHP blood using magnetic beads and conducted studies on the effect of Mtb infection on antigen presentation using confocal immuno-fluorescence techniques.
11/2002 to 02/2008
Postdoctoral Fellow Aaipharma Wilmington, NC,
  • Conducted research on developing L2 based prophylactic vaccines against Human papillomavirus (HPV) infection and understanding the role of L2 protein in HPV infection.
  • Developed a broadly protective protein and peptide based vaccines against cervical cancer.
  • Discovered a novel Monoclonal antibody (RG-1) that protected against HPV infection both in vitro and in vivo (mouse model).
  • Succeeded in developing a mouse model for HPV16 infection.
  • Performed extensive work on understanding the mechanism of papillomavirus entry into the susceptible cells using microarrays.
  • Performed in vitro assays for identifying the receptor(s) for viral entry.
06/2000 to 11/2002
Research Trainee/Fellow MD ANDERSON CANCER CENTER City, STATE,
  • Studied "the safety and potential of cholera toxin mutant as a novel mucosal adjuvant".
  • used a novel adjuvant in combination with peptides derived from both Human immunodeficiency virus (HIV) and HPV for eliciting T and B cell responses in mouse models.
  • Collected several blood samples from HPV infected patients and analyzed their immune response to HPV E6 and E7 derived peptides using Enzyme-linked-immunospot assays (ELISPOT)s, FACS and T cell proliferation assays.
Current to Current
Scientist SYNGENE INTERNATIONAL PVT LTD City, STATE, India
  • Involved in developing highly permeable strains of E.coli using gene replacement methodologies.
  • Optimized methods for yeast transfection for expression of recombinant proteins Jessica Claire, DVM, MS, PhD, DACVM, MB (ASCP) CM ADDITIONAL TRAINING.
  • Participated in Veterinary Pathology Training.
  • Familiar with drafting Institutional Animal Care and Use Committees(IACUC), Institutional review board (IRB) and Institutional Biosafety Committee (IBC) proposals.
  • Trained and mentored both graduate and postdoctoral students.
  • Written several research proposals.
Affiliations
Diplomate, Virology- American College of Veterinary Microbiologists (ACVM) *MB-Technologist in Molecular Biology-MB (ASCP) CM (American Society for Clinical Pathology)
Education
Expected in May 2012 to to
Ph.D: Biomedical Sciences Virology and Immunology
TULANE UNIVERSITY - New Orleans, LA
GPA:
Biomedical Sciences Virology and Immunology Completed program with broad scope covering areas of microbiology, immunology, pathology and biostatistics *Submitted thesis on "Characterization of viral envelopes and cytokine responses among rhesus macaques immunized with vesicular stomatitis virus-based simian immunodeficiency virus (SIV) vaccines and challenged with pathogenic SIV"
Expected in 1997 to to
MS: Animal Biotechnology
INDIAN VETERINARY RESEARCH INSTITUTE - Izatnagar, India
GPA:
Animal Biotechnology
Expected in March 1994 to to
DVM: Veterinary Science and Animal Husbandry
COLLEGE OF VETERINARY SCIENCES - Tirupathi, India
GPA:
Veterinary Science and Animal Husbandry (D.V.M.) *Studied several courses related to animal health and husbandry *Attended clinical rounds in veterinary medicine, surgery and obstetrics and Gynecology
Publications
Schell JB, Bahl K, Diller K, Folta-Stogniew E, Rose N, Buonocore L, Marx PA, Claire R, and Rose JK (2015). Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus. Virology. Feb; Epub 2015 Jan 12. *Claire R, Keele BF, Schell JB, Hunter MJ, Dufour JP, Montefiori DC, Tang HK, Rose JK, Rose N and Marx PA (2014). SGA analysis of viral envelope sequences in VSV-SIV vaccinated and SIVsmE660 challenged rhesus macaques. PLoS One.Oct; 9(10): eCollection 2014. *Berg MG, Adams RJ, Claire R, Siracusa MC, Scott Al, Roden RB and Ketner G (2014). Immune responses in macaque to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine. Clin Vaccine Immunol. Sep; 21(9):1224-31 *Schell JB, Rose NF, Bahl K, Diller K, Buonocore L, Hunter M, Marx PA, Claire R, Tang H, Montefiori DC, Johnson WE and Rose JK (2011). Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost regimen. J Virol. Jun; 85(12):5764-72. *Claire R, Jagu S, Karanam B, Day PM and Roden R (2009). Role of L2 cysteines in papillomavirus infection and neutralization. Virol J. Oct 27; 6:176. *Jagu S, Karanam, B, Claire R, Chivukula SV, Chaganti R, Schiller JT and Roden RBS (2009). Concatenated Multi-type L2 Fusion Protein as a Prophylactic Human Papillomavirus Vaccine. Journal of the National Cancer Institute. Jun 3; 101(11): 782-92. Epub 2009 May 26 *Zhenhua Lin Claire R, Jagu S, Kirnbauer R, Meyers C and Roden RBS (2009). Sub cellular localization of Human papillomavirus minor capsid protein L2 differs upon ectopic versus endogenous expression. American Journal of Pathology. Jan; 174(1): 136-43 *Handisurya A, Claire R,Schellenbacher C,Shafti-Keramat S, Forslund O, Favre M, Kirnbauer R (2009). Serological relationship between cutaneous human papillomavirus types 5, 8 and 92. Journal of General Virology. Jan; 90(Pt 1): 136-43. *Karanam B, Claire R, Roberts JN, Peng S, Jagu S, Kim D, Ketner G, Adams R, Roden RBS (2009). Vaccination with TA-CIN (L2E6E7) and semi-synthetic quillaja saponin analog GPI-0100 elicits protective humoral and tumor immunity. Vaccine. Feb 11; 27(7): 1040-9. *Alphs H*, Claire R*, Karanam B, Roderts JN, Jagu S, Schiller JT, Zeng W, Jackson DC, Roden RBS (2008). A synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of minor capsid protein L2 protects against heterologus human papillomavirus challenge. (*both the authors contributed equally). Proceedings of the National Academy of Sciences. Apr; 105(15): 5850-5. *Jessica Claire, DVM, MS, PhD, DACVM, MB (ASCP) CM Day PM, Claire R, Roden R, Lowy DR, Schiller JT (2008). Mechanism of HPV 16 Neutralization by L2-cross neutralizing and L1 type-specific antibodies. J.Virol. May; 82(9): 4638-46. *Kim D, Claire R, Karanam B, Monie A, Hung CF, Roden R, Wu TC (2008). Generation and Characterization of a preventive and therapeutic HPV DNA Vaccine. Jan; 26(3): 351-60. *Claire R, Karanam B, Jagu S, Roberts J, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RB (2007). A protective and broadly cross-neutralizing epitope of Human papillomavirus L2. J Virol. Dec; 81(24): 13927-31 *Claire R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, Roden RB (2007). Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N- terminus of HPV16 minor capsid antigen L2. J Virol. Nov; 81(21): 11585-592. *Manuri PR, Nehete B, Nehete PN, Reisnauer R, Wardell S, Courtney AN,Claire R, Lomada D, Chopra AK, Jagannadha Sastry K (2007). Intranasal immunization with synthetic peptides corresponding to E6 and E7 oncoproteins of human papillomavirus type16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine. Apr; 25(17): 3302-10 *Claire R, Gravitt PE, Bossis I, Stern PL, Viscidi RP, Roden RBS (2006). Vaccination of healthy volunteers with Human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Research. Dec; 66(23): 1-4. *Slupetzky K, Claire R, Culp TD, Shafti-KeramatS, Schellenbacher C, Christensen ND, Roden RBS, Kirnbauer R (2006). A papillomavirus-like particle (VLP) vaccine displaying HPV16L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine March; 25(11): 2001-10. *Berg M, Claire R, Siracusa M, Hoiczyk E, Roden R, Ketner G (2006). HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice. Vaccine. Apr; 25(17): 3501-10. *Bossis I, Roden RB, Claire R, Yang R, Tagaya M, Howley P, Meneses PI (2005). Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J Virol. Jun; 79(11): 6723-31. *Pastrana DV, Claire R, Buck CB, Pang YYS, Thompson CD, Lowy DR, Schiller JT and Roden RB (2005). Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti- sera to the amino terminus of L2. Virology. Jul; 337(2): 365-372. *Lomada D,Claire R, Nehete PN, Guhad FA, Chopra AK, Peterson, JW, Sastry KJ (2004). A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens. Vaccine. Dec; 23 (4): 555-65 *Nehete PN, Claire R, Nehete BP, Sastry KJ (2003). Dendritic cells enhance detection of antigen-specific cellular immune responses by lymphocytes from rhesus macaques immunized with an HIV envelope peptide cock tail vaccine. J Med Primatol. Apr; 32(2): 67-73 *Sastry KJ, Nehete PN, Claire R, Nehete BN, Keeney TS. (2001). Synthetic peptide-based vaccines for induction of cell-mediated immunity against human immunodeficiency virus (HIV) and human papillomavirus (HPV). Recent Res. Devel. Virol. 3: 575-601. *Suryanarayana V.V.S, Viswanathan S, Jessica G, Pradeep Bist, Prabhudas K, Gajendragad M.R., and Natarajan C. (1999): E-coli expressed proteins as diagnostic reagents for typing of foot and mouth disease virus. Archives of Virology. 144(9): 1701-12 *Jessica G, Viswanathan S, Reddy G.R, Suryanarayana V.V.S. (1999). Type specific protein antigens of foot-and-mouth disease virus: Expression in E-coli and affinity purification. Acta Virol. Aug; 43(4): 205-11. *Viswanathan S, Jessica G, Reddy G.R, Suryanarayana V.V.S. (1999): Comparative studies of immuno reactivity of truncated recombinant proteins of FMDV produced in E-coli and insect cells. Ind. J. Exp. Biol. Jun; 37(6): 536-40.
Interests
Co-inventor on a patent filed on "Papillomavirus N-terminal peptides for the induction of broadly cross neutralizing antibodies" *Co-inventor of the "RG-1 Monoclonal Antibody" that could neutralize both human papillomavirus (HPV) 16 and 18 infections in vitro *Co-inventor on the L2 based Lipopeptide vaccine for prevention of HPV infection
Accomplishments
  • AWARDS                                                                                                                                           

     

    • 2010-13- Received The Ruth L. Kirschstein National Research Service Awards (NRSA) fellowship

    • 2009- Presented with Beginning Scientist Award from Tulane University

    • 2006-Won an award for Excellence in Basic Research at Eighth Annual Pathology Young investigators’ Day held in Johns Hopkins University

    • Jessica Claire, DVM, MS, PhD, DACVM, MB (ASCP) CM

       

      2006-Awarded NCI travel scholarship to present the work at DNA tumor virus meeting in San Diego, CA

    • 2005 Won an award for Excellence in Basic Research at Seventh Annual Pathology Young investigators’ Day held in Johns Hopkins University

    • 1995-Awarded Department of Science and Technology fellowship for Master’s research Program

  • PATENTS                                                                                                                                          

     

    • Co-inventor on a patent filed on “Papillomavirus N-terminal peptides for the induction of broadly cross neutralizing antibodies”

    • Co-inventor of the “RG-1 Monoclonal Antibody” that could neutralize both human papillomavirus (HPV) 16 and 18 infections in vitro

    • Co-inventor on the L2 based Lipopeptide vaccine for prevention of HPV infection

     

Certifications
  • Diplomate, Virology- American College of Veterinary Microbiologists (ACVM)

  • MB-Technologist in Molecular Biology-MB (ASCP) CM (American Society for Clinical Pathology)

  • ABB- Technical Supervisor- TS (ABB) (American Board of Bioanalysis)

Additional Information
  • AWARDS *2010-13- Received The Ruth L. Kirschstein National Research Service Awards (NRSA) fellowship *2009- Presented with Beginning Scientist Award from Tulane University *2006-Won an award for Excellence in Basic Research at Eighth Annual Pathology Young investigators' Day held in Johns Hopkins University *Jessica Claire, DVM, MS, PhD, DACVM, MB (ASCP) CM 2006-Awarded NCI travel scholarship to present the work at DNA tumor virus meeting in San Diego, CA *2005 Won an award for Excellence in Basic Research at Seventh Annual Pathology Young investigators' Day held in Johns Hopkins University *1995-Awarded Department of Science and Technology fellowship for Master's research Program PATENTS *Co-inventor on a patent filed on "Papillomavirus N-terminal peptides for the induction of broadly cross neutralizing antibodies" *Co-inventor of the "RG-1 Monoclonal Antibody" that could neutralize both human papillomavirus (HPV) 16 and 18 infections in vitro *Co-inventor on the L2 based Lipopeptide vaccine for prevention of HPV infection

By clicking Customize This Resume, you agree to our Terms of Use and Privacy Policy

Your data is safe with us

Any information uploaded, such as a resume, or input by the user is owned solely by the user, not LiveCareer. For further information, please visit our Terms of Use.

Resume Overview

School Attended

  • TULANE UNIVERSITY
  • INDIAN VETERINARY RESEARCH INSTITUTE
  • COLLEGE OF VETERINARY SCIENCES

Job Titles Held:

  • Pharmacogenomics Lab Manager
  • Instructor
  • Research Fellow
  • Postdoctoral Fellow
  • Research Trainee/Fellow
  • Scientist

Degrees

  • Ph.D
  • MS
  • DVM

By clicking Customize This Resume, you agree to our Terms of Use and Privacy Policy

*As seen in:As seen in: